GT BIOPHARMA, INC.
9350 Wilshire Blvd. Suite 203
Beverly Hills, CA 90212
September 26, 2019
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
|
|
Re:
|
GT Biopharma, Inc.
|
|
|
|
Registration Statement on Form S-1 (File No. 333-233748)
|
|
|
|
Request for Acceleration of Effective Date
|
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, GT Biopharma, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-233748) and declare the Registration Statement effective as of Wednesday, October 2, 2019, at 4:00 p.m., Eastern time, or as soon as practicable thereafter.
Please contact the undersigned at (407) 808-7704, or Gary R. Henrie, Attorney at Law at (307) 200-9415, with any questions. Also, please notify Mr. Henrie when this request for acceleration has been granted.
|
|
Very truly yours,
GT Biopharma, Inc.
|
|
|
|
|
|
|
| |
By:
|
/s/ Steven Weldon
|
|
|
|
|
Name: Steven Weldon
Title: Chief Financial Officer
|
|
|
|
|
|
|
|
cc: Gary R. Henrie, Attorney at Law
|
|
|
|